<DOC>
	<DOCNO>NCT00537407</DOCNO>
	<brief_summary>Debio 025 ( alisporivir ) oral cyclophilin inhibitor new mechanism action demonstrate potent anti-hepatitis C virus ( HCV ) activity pre-clinical model patient . The current standard care ( SOC ) HCV patient consist combination peg-IFN alpha ribavirin . Treatment duration ribavirin dose depend genotype treat . Only 40-50 % patient genotype 1 achieve sustain viral response ( SVR ) . This study assess whether Debio 025 administer combination peg-IFN alpha 2a ribavirin improve outcome treatment group patient .</brief_summary>
	<brief_title>A Study Debio 025 Combination With PegIFN Alpha-2a Ribavirin Chronic HCV Patients Non-responders Standard Treatment</brief_title>
	<detailed_description>This multicentre , open-label , randomize , 5 arm parallel-group , multiple dose study 50 chronic hepatitis C virus ( HCV ) genotype 1 non-responders standard treatment peg-IFN alpha ( 2a 2b ) ribavirin . The entire study last maximum 96 week consist 48- 72-week treatment period ( accord response ) . A follow-up visit ass sustain viral response ( SVR ) take place 24 week treatment cessation , i.e. , study Week 72 96 , early discontinue study participant . There 2 part treatment period . Part 1 lasted Day 1 Day 29 ( Weeks 1 4 ) ; Part 2 last Week 5 Week 48 72 . During Part 1 treatment ( Weeks 1 4 ) , participant randomize 1 5 treatment arm receive 4 week Debio 025 ( alisporivir ) monotherapy , Debio 025 combine standard dose peg-IFNα2a , 1 3 triple therapy combine different dos Debio 025 peg-IFNα2a ribavirin standard dos . During Part 2 treatment ( Weeks 5 48 72 ) , participant receive standard dos peg-IFNα2a/ribavirin dual therapy 44 68 week , depend response treatment . At Week 12 , participant achieve ≥ 2 log10 decrease HCV RNA withdrawn consider treatment failure . Participants undetectable HCV RNA level and/or ≥ 2 log10 decrease HCV RNA continue treatment Week 24 . At Week 24 , participant still detectable HCV RNA level withdraw consider treatment failure . Participants undetectable HCV RNA level Weeks 12 24 continue treatment Week 48 . At Week 24 , `` slow responder '' ( defined participant detectable , &gt; 2 log10 decrease HCV RNA level Week 12 undetectable level Week 24 ) eligible continue treatment Week 72 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Male female patient 18 60 year age . Hepatitis B negative human immunodeficiency virus ( HIV ) negative . Diagnosed hepatitis C genotype I responsive treatment peginterferon alpha2a 2b ribavirin least 12 week . Adequate liver function ( ChildPughTurcotte score A ) laboratory parameter within acceptable range . Females may participate become pregnant , i.e. , surgically sterile , postmenopausal , use 2 reliable contraceptive method . Male patient must surgically sterile utilize barrier contraceptive method . For female patient child bear potential , negative pregnancy test within 1 week first investigational product administration . Treatment investigational drug within 6 month prior start study . Ongoing recent use antiviral medication within 1 month start study . A known bad reaction intolerance Debio 025 , peginterferon alpha2a , and/or ribavirin . Presence history severe related disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>